Brief: Clover’s COVID Vaccine Candidate Demonstrates Durable High Protection, Immune Responses Against Omicron As A Booster

Clover Biopharmaceuticals

17/03/2022 11:12

March 17 (Reuters) - Clover Biopharmaceuticals Ltd
 2197.HK :
    * CLOVER’S COVID-19 VACCINE CANDIDATE DEMONSTRATES DURABLE
HIGH
PROTECTION AND IMMUNE RESPONSES AGAINST OMICRON AS A BOOSTER
    * CLOVER BIOPHARMA - 100% EFFICACY MAINTAINED AGAINST SEVERE
COVID-19 AND 95% EFFICACY AGAINST HOSPITALIZATION AT 5 MONTHS
AFTER 2ND DOSE OF SCB-2019
    * CLOVER BIOPHA - SIGNIFICANT NEUTRALIZING ANTIBODIES
AGAINST
OMICRON INDUCED BY SCB-2019 THIRD DOSE IN BOTH HOMOLOGOUS AND
HETEROLOGOUS BOOSTER SETTINGS

Source text for Eikon:  ID:nGNX17pVwl 
Further company coverage:  2197.HK